Genitourinary Cancers

New NCCN guidelines regarding genomic profiling will likely yield important opportunities to improve the care of patients with advanced bladder cancer.

A new study has found a series of potential microRNA biomarkers that could predict tyrosine kinase inhibitor response in RCC patients.

In this paper, we review the use of serum tumor markers in risk assignment and response evaluation; the treatment of previously untreated and relapsing patients; the role of surgical resection of residual disease, including retroperitoneal node dissection; and the importance of clinical trials for addressing unanswered questions and testing new therapies.

Metastatic prostate cancer is more strongly associated than localized disease with germline mutations in DNA repair genes like BRCA1 and BRCA2.

Canadian researchers have tentatively identified urine protein signatures that appear to differentiate aggressive from low-risk prostate tumors.

Both African-American and Caucasian patients with advanced RCC have seen improved survival with targeted therapies, though African-Americans still experience survival disadvantages.

A randomized phase III trial found that a hypofractionated radiotherapy regimen was not superior to, but generally equivalent to a conventional radiotherapy scheme in men with localized prostate cancer.

Compared to everolimus, the oral tyrosine kinase inhibitor cabozantinib improves objective tumor response, delays disease progression, and prolongs overall survival time among patients with RCC.

A database analysis showed that the addition of external beam radiotherapy to ADT significantly improves overall survival in men with metastatic prostate cancer.

Higher than average PSA levels in middle age may be predictive of a higher risk of lethal prostate cancer later in life.

Long-term follow-up of a phase I and a phase II study shows that nivolumab produces strong overall survival benefit in patients with advanced renal cell carcinoma.

Patients with metastatic RCC who undergo cytoreductive nephrectomy plus targeted therapy have better survival over those treated only with targeted therapy.

Cabozantinib significantly improved the overall survival of patients with previously treated advanced RCC, according to the second interim analysis of the METEOR trial.

In this peer-to-peer discussion Dr. Grivas and Dr. Palmbos examine the role of neoadjuvant chemotherapy in bladder cancer and weigh the various trial data guiding these treatment decisions.

In this review, we summarize the diagnosis of small renal masses, the role of renal mass biopsy, different treatment strategies, and future directions, including emerging molecular biomarkers.

More research is needed to define the optimal radiotherapy and chemotherapy regimen for male urethral carcinoma. However, modern chemoradiation is a feasible treatment option for motivated men with urethral carcinoma who want to preserve their organs.

This article will review select novel targets and approaches relevant to urothelial cancer.

Since the development of first-line cisplatin-based combination chemotherapy with methotrexate, vinblastine, doxorubicin, and cisplatin almost 3 decades ago, there have not been major advances in the treatment of this disease.

Patients with T1 bladder cancer on re-resection achieve the best possible survival benefit by IRC and thorough pelvic lymph node dissection.

Nivolumab is safe and effective in patients with metastatic bladder cancer refractory to prior lines of platinum-based chemotherapy, according to findings from the open-label, phase I/II CheckMate 032 trial.

Experimental, minimally invasive “liquid biopsy” blood tests might soon help to personalize prostate cancer treatment by predicting androgen resistance and survival benefits from particular treatments.

Anti-programmed cell death protein 1 (PD-1) checkpoint inhibitor immunotherapy with nivolumab is safe and effective even after disease progression among patients with metastatic RCC.

The majority of patients with clear cell renal cancer saw benefit from pazopanib therapy prior to undergoing cytoreductive nephrectomy, according to a single-arm study.

A phase II trial found that cabozantinib offers significantly better progression-free survival over sunitinib in patients with untreated advanced RCC.

The higher incidence of bladder cancer in the Northeast in the last 50 years may be attributed to the presence of arsenic in the drinking water, according to a new study.

A new study published in Nature Communications is suggesting that castration-resistant prostate cancer has particular metabolic characteristics that may open new possibilities for treatment.

A team of surgeons performed the first genitourinary reconstructive penile transplant in the United States on a patient whose penis was removed due to a rare form of penile cancer.

The fatty acid DHA, a component of fish oil, might enhance regorafenib’s ability to slow angiogenesis and tumor growth in renal cell carcinoma.

The FDA has granted accelerated approval to atezolizumab (Tecentriq) for the treatment of locally advanced or metastatic urothelial carcinoma-the most common type of bladder cancer.

Partial nephrectomy yields similar oncologic outcomes to radical nephrectomy for patients with stage T3a renal tumors after 5 years, according to results of a new study.